Genmab A (GMAB) Depreciation & Amortization - Total (2019 - 2020)
Genmab A (GMAB) reported Depreciation & Amortization - Total of $4.0 million for Q3 2020, down 16.54% on a YoY basis from $4.8 million in Q4 2019, and little changed quarter-over-quarter from $4.0 million in Q4 2019.
Genmab A (GMAB) Depreciation & Amortization - Total (2019 - 2020) Analysis & Trends
Genmab A has reported Depreciation & Amortization - Total for 2 years, with the latest figure at $4.0 million in Q3 2020.
- For the quarter ending Q3 2020, Depreciation & Amortization - Total fell 16.54% year-over-year to $4.0 million; the trailing twelve-month figure through Sep 2020 stood at $4.0 million (down 16.54% YoY), and the FY2019 full-year result was $4.0 million, changed N/A from the prior year.
- Depreciation & Amortization - Total for Q3 2020 stood at $4.0 million, roughly flat from $4.0 million in the prior quarter.
- The five-year high for Depreciation & Amortization - Total was $4.8 million in Q3 2019, with the low at $4.0 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 4.00 Mn |
| Dec 31, 2019 | 4.00 Mn |
| Sep 30, 2019 | 4.79 Mn |